WP
JSPR icon

Woodline Partners’s Jasper Therapeutics JSPR Stock Holding History

Woodline Partners’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,040,704
Closed -$1.9M – 1105
2025
Q4 		$1.9M Buy
1,040,704
+953
+0.1% +$1.91K 0.01% 775
2025
Q3 		$2.47M Buy
+1,039,751
New +$3.15M 0.01% 697
2025
Q1 		– Sell
-245,676
Closed -$5.25M – 970
2024
Q4 		$5.25M Sell
245,676
-249,428
-50% -$5.19M 0.04% 478
2024
Q3 		$9.31M Buy
495,104
+81,164
+20% +$1.62M 0.08% 310
2024
Q2 		$9.4M Buy
413,940
+34,694
+9% +$832K 0.09% 255
2024
Q1 		$11.1M Buy
379,246
+205,947
+119% +$3.66M 0.1% 247
2023
Q4 		$1.37M Sell
173,299
-126,701
-42% -$850K 0.01% 394
2023
Q3 		$2.1M Hold
300,000
– – 0.02% 396
2023
Q2 		$4.11M Hold
300,000
– – 0.05% 322
2023
Q1 		$5.43M Buy
+300,000
New +$5.55M 0.07% 285

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Woodline Partners's JSPR Position: Q1 2026 in Review

Woodline Partners sold out of Jasper Therapeutics (JSPR) in Q1 2026, closing a stake of 1,040,704 shares — an estimated $1.9M sold.

Woodline Partners first reported a position in JSPR in Q1 2023 and held it in 10 quarters. The position peaked at $11.1M in Q1 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

  • Woodline Partners reported no remaining Jasper Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Woodline Partners sold 1,040,704 Jasper Therapeutics shares in Q1 2026, an estimated $1.9M.
  • Woodline Partners first reported a position in Jasper Therapeutics in Q1 2023 and held it in 10 quarters.
  • Woodline Partners's Jasper Therapeutics position peaked at $11.1M in Q1 2024.
  • 58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.